Physician profile
Michael Rosario-Prieto
NPI 1871738948
$167,084.06
in general payments reported to CMS, 2019-2025
65 companies · $50K in 2025
The $50K reported for 2025 was more than what 92% of Neuromuscular Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $530).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,144 · 2020: $705 · 2021: $1,200 · 2022: $12K · 2023: $25K · 2024: $76K · 2025: $50K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $116K · Food and Beverage: $13K · Travel and Lodging: $11K · Consulting Fee: $10K · Education: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $116,385.00 |
| Food and Beverage | $12,940.63 |
| Travel and Lodging | $11,443.32 |
| Consulting Fee | $10,335.00 |
| Education | $250.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $102,217.00 | 2019-2025 | Zilbrysq, Rystiggo, Fintepla |
| Argenx US, INC. | $44,950.56 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Ucb Sa | $3,995.00 | 2024 | Rystiggo |
| Amgen INC. | $2,487.81 | 2019-2025 | Uplizna, Tavneos |
| Alexion Pharmaceuticals, INC. | $1,657.99 | 2019-2025 | Ultomiris, Soliris |
| Abbvie INC. | $1,228.46 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $710.58 | 2019-2025 | |
| Allergan, INC. | $676.96 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $630.86 | 2022-2025 | Hyqvia, Gammagard |
| Biogen, INC. | $575.79 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Genentech USA, INC. | $569.90 | 2019-2025 | Evrysdi, Ocrevus |
| Pfizer INC. | $526.74 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $472.04 | 2019-2025 | Austedo Xr, Austedo Xr |
| Ge Healthcare | $471.28 | 2020-2024 | |
| Tanabe Pharma America, INC. | $468.91 | 2023-2025 | Radicava |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $414.09 | 2019-2025 | Ingrezza, Ongentys |
| Lundbeck LLC | $378.48 | 2023-2025 | Vyepti, Rexulti |
| Csl Behring | $357.22 | 2019-2025 | Hizentra |
| Sk Life Science, INC. | $309.26 | 2022-2025 | Xcopri |
| Lilly USA, LLC | $288.56 | 2019-2024 | Reyvow, Emgality, Amyvid |
| Acorda Therapeutics, INC | $284.35 | 2019-2024 | Inbrija, Ampyra |
| Catalyst Pharmaceuticals, INC. | $253.84 | 2019-2025 | Firdapse |
| Vanda Pharmaceuticals INC. | $199.86 | 2024-2025 | Ponvory |
| Janssen Biotech, INC. | $194.07 | 2025 | |
| Acadia Pharmaceuticals INC | $187.77 | 2019-2024 | Nuplazid |
| Genzyme Corporation | $178.83 | 2019-2025 | |
| Eisai INC. | $160.62 | 2022-2024 | |
| Sumitomo Pharma America, INC. | $147.28 | 2023-2024 | Aptiom |
| Portola Pharmaceuticals, LLC | $141.39 | 2019-2020 | |
| Silk Road Medical, INC. | $137.57 | 2019 | |
| Merz Pharmaceuticals, LLC | $114.90 | 2024-2025 | Xeomin |
| Aucta Pharmaceuticals, INC. | $112.99 | 2024-2025 | Motpoly Xr |
| Upsher-Smith Laboratories LLC | $106.05 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $103.66 | 2019-2022 | |
| Alnylam Pharmaceuticals INC. | $97.19 | 2019-2025 | Onpattro |
| Jazz Pharmaceuticals INC. | $95.56 | 2020-2025 | Xywav |
| Banner Life Sciences, LLC | $95.53 | 2022-2023 | |
| Emd Serono, INC. | $94.23 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $88.55 | 2019 | |
| Sarepta Therapeutics, INC. | $81.52 | 2019-2024 | Elevidys |
| Grifols USA, LLC | $78.56 | 2019-2025 | Gamunex-C |
| Astrazeneca Pharmaceuticals Lp | $77.82 | 2023-2025 | Andexxa, Evusheld, Wainua |
| Axsome Therapeutics, INC. | $75.57 | 2025 | Symbravo |
| Biohaven Pharmaceutical Holding Company Ltd. | $66.38 | 2022 | |
| Xeris Pharmaceuticals, INC. | $65.29 | 2022-2024 | Keveyis |
| Neurelis, INC. | $39.99 | 2024 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $38.45 | 2021 | |
| Tg Therapeutics, INC. | $34.79 | 2025 | |
| Harmony Biosciences LLC | $29.95 | 2022 | |
| Zyla Life Sciences, INC. | $27.82 | 2020 | |
| Avanir Pharmaceuticals, INC. | $25.89 | 2019-2020 | |
| Mdd US Operations, LLC | $25.84 | 2020 | |
| C2n Diagnostics, LLC | $22.94 | 2025 | Precivityad2 |
| Microtransponder, INC. | $22.13 | 2025 | |
| Vertical Pharmaceuticals, LLC | $20.99 | 2019 | |
| Tonix Medicines, INC. | $20.50 | 2025 | Zembrace Symtouch |
| Livanova USA, INC. | $19.68 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Corium, LLC | $19.26 | 2023 | Adlarity |
| Cycle Pharmaceuticals INC | $17.86 | 2025 | Tascenso Odt |
| Itf Therapeutics LLC | $16.94 | 2024 | |
| Amylyx Pharmaceuticals, INC. | $16.70 | 2023 | Relyvrio |
| Idorsia Pharmaceuticals US INC | $16.21 | 2023 | Quviviq |
| Kyowa Kirin, INC. | $15.95 | 2019 | |
| Celgene Corporation | $12.73 | 2023 | Zeposia |
| Ptc Therapeutics, INC. | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rosario-Prieto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.